A Message From the Chair

As 2020 commences it is important reflect on what has been achieved at the ANZAC Research Institute in 2019. The ARI is nothing without its fantastic medical researchers who are the engine room of innovation. I continue to be impressed by the calibre and impact of the research across a range of scientific and therapeutic areas.

As we see in [our latest newsletter], Associate Professor Georgina Clark has linked with Kira Biotech to translate fundamental research from bench to bedside, putting the ARI at the frontline in treating immune disorders. NHMRC research grant funding continues to be intensely competitive, so it was heartening to see that teams led by Prof Marina Kennerson and Prof Hong Zhou have been awarded Ideas Grants, reflecting both the calibre of the research and innovative ideas generated in the ARI. These achievements come from our ability to create the right environment for researchers to be successful. I extend the sincere thanks of the board to our Director, Professor David Handelsman, who continues to lead with energy and drive, as he has done for the past 20 years.

This year we celebrate 20 years of the ANZAC Research Institute and planning is underway for suitable events to recognise this great achievement and plan for the next 20 years. The board recently finalised the terms of reference for a strategic review with a view to ensuring the ARI remains at the forefront of high quality medical research. The board continues to work on the strategic plan with a focus on the priority issues of fundraising, strengthening partnerships and sustainability including succession plans for the ARI leadership.

My special thanks to Professor Bob Lusby, former chair, for his leadership and stewardship over many years. Bob has made a lasting impact. I thank all board members for their passion and commitment to the ARI, with special thanks to Kerry Hogan Ross and Paul Levins who step down after years of faithful service. We welcome to the board Professor Mark Rees, Deputy Dean at the University of Sydney, and Gillian Davidson, a partner at Sparke Helmore Lawyers. Lastly, I would like to thank our key partners, the Sydney Local Health District and the University of Sydney, for their support and effective collaboration.